Tags : Almirall


NICE Publishes Final Recommendation for Almirall’s Ilumetri (tildrakizumab) to Treat

Shots: NICE has recommended Ilumetri (tildrakizumab) as a cost-effective option for the treatment of adults patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy following its assessment submission in Aug’18 Ilumetri (tildrakizumab) is evaluated in P-III reSURFACE 1 and 2 study in 1,800 patients > 200 sites across the globe resulted in maintaining […]Read More


Almirall Signs a Research Collaboration with HitGen for its DNA-Encoded

Shots: HitGen to receive upfront & milestones from Almirall to develop novel small molecules for Almirall’s target The focus of the collaboration is to utilize HitGen’s technology based on DNA-encoded library design, synthesis and screening, in identifying small molecules for the treatment of atopic dermatitis HitGen’s DELs is a drug discovery platform including 400B macrocyclic […]Read More


Almirall’s Ilumetri (tildrakizumab) Receives NICE’s Provisional Approval for Moderate-To-Severe Plaque

Shots: The approval is based on P-III reSURFACE 1 & reSURFACE 2 studies assessing Ilumetri (tildrakizumab) in 1,800 patients with moderate-to-severe plaque psoriasis across 200 sites WW reSURFACE 1 & reSURFACE 2 studies result: @12wks. PASI 75 (75%); @28wks. PASI 90 (54%), PASI 100 (29%); well tolerated; low AEs & discontinuation rates Ilumetri (tildrakizumab, SC, […]Read More